Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 41-50 of 9381

Page
per page
  1. Carbenoxolone disodium
    A8389 Carbenoxolone disodium
     1 Citation
    Target: Gap Junctions
    Summary: 11β-HSD inhibitor
      ≥30.74 mg/mL
  2. RGFP966
    A8803 RGFP966
     4 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: Specific HDAC3 inhibitor
      insoluble in H2O; ≥18.12 mg/mL
  3. Amyloid Beta-Peptide (1-40) (human)
    A1124 Amyloid Beta-Peptide (1-40) (human)
     1 Citation
    Summary: residues 1-40 of human amyloid-beta
      insoluble in EtOH; ≥23.8 mg/mL
  4. Urolithin A
    B7945 Urolithin A
      ≥22.8 mg/mL
  5. Tamoxifen
    B5965 Tamoxifen
     17 Citation
    Target: PKC
    Summary: estrogen receptor modulator
      ≥18.6 mg/mL
  6. Nitrocefin
    B6052 Nitrocefin
     2 Citation
    Summary: chromogenic substrate of β-lactamase enzymes
      insoluble in EtOH; insoluble in H2O; ≥20.24 mg/mL
  7. Oleandomycin
    C3213 Oleandomycin
    Summary: macrolide antibiotic
      Soluble in DMSO
  8. Mebendazole
    C4087 Mebendazole
    Summary: broad-spectrum anthelmintic that inhibits intestinal microtubule synthesis
      insoluble in H2O; insoluble in EtOH; ≥13 mg/mL
  9. Vitamin D3
    B2065 Vitamin D3
    Summary: Fat-soluble secosteroids
      insoluble in H2O; ≥51.6 mg/mL
  10. (-)-Blebbistatin
    B1387 (-)-Blebbistatin
     9 Citation
    Target: Myosin II ATPases
    Summary: non-muscle myosin II inhibitor
      insoluble in EtOH; insoluble in H2O; ≥14.62 mg/mL

Items 41-50 of 9381

Page
per page